In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ergonex Pharma GmbH

www.ergonex.com

Latest From Ergonex Pharma GmbH

Deals Shaping the Medical Industry (06/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Pfizer acquires rights to terguride for pulmonary arterial hypertension

Pfizer has acquired the rights to the pulmonary arterial hypertension (PAH) drug candidate terguride from Swiss firm Ergonex Pharma.

Cardiovascular Metabolic Disorders
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Ergonex Pharma GmbH
  • Senior Management
  • Rudolf Reiter, CEO
  • Contact Info
  • Ergonex Pharma GmbH
    Phone: (41) 71 788 4065
    Rütistrasse 20
    Appenzell, CH-9050
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register